Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 14/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18183054 | 0.94 | MRGPRX4 (0.46) | MRGPRX4KCNK3KCNK9RXRARXRB | |
| SCHEMBL18183065 | 0.94 | MRGPRX4 (0.44) | MRGPRX4KCNK3KCNK9RXRARXRB | |
| SCHEMBL18182582 | 0.94 | MRGPRX4 (0.44) | MRGPRX4KCNK3KCNK9FABP3FABP4 | |
| SCHEMBL18183067 | 0.94 | MRGPRX4 (0.46) | MRGPRX4KCNK3KCNK9FABP3FABP4 | |
| SCHEMBL18182580 | 0.92 | MRGPRX4 (0.42) | MRGPRX4 | |
| SCHEMBL18183072 | 0.92 | MRGPRX4 (0.45) | MRGPRX4KCNK3KCNK9RXRARXRB | |
| SCHEMBL18182581 | 0.92 | MRGPRX4 (0.42) | MRGPRX4KCNK3KCNK9FABP3FABP4 | |
| SCHEMBL18183066 | 0.92 | MRGPRX4 (0.45) | MRGPRX4FABP3FABP4FABP5FGFR4 | |
| SCHEMBL18532847 | 0.92 | MRGPRX4 (0.42) | MRGPRX4KCNK3KCNK9FFAR1FFAR4 | |
| SCHEMBL18183034 | 0.92 | MRGPRX4 (0.42) | MRGPRX4KCNK3KCNK9RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3081559-A1 | AROMATIC COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Limited (JP) | 2016-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | MRGPRX4 167/4885KCNK3 463/4885KCNK9 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.